1. 1242. Safety and Immunogenicity of Novel 24-Valent Pneumococcal Vaccine in Healthy Adults. (31st December 2020) Authors: Chichili, Gurunadh; Smulders, Ronald; Santos, Vicki; Cywin, Beth; Kovanda, Laura; Malinoski, Frank J; Sebastian, Shite; Siber, George R; Malley, Rick Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. (March 2021) Authors: Ljungman, Per; Bermudez, Arancha; Logan, Aaron C.; Kharfan-Dabaja, Mohamed A.; Chevallier, Patrice; Martino, Rodrigo; Wulf, Gerald; Selleslag, Dominik; Kakihana, Kazuhiko; Langston, Amelia; Lee, Dong-Gun; Solano, Carlos; Okamoto, Shinichiro; Smith, Larry R.; Boeckh, Michael; Wingard, John R.; Cyw... Journal: EClinicalMedicine Issue: Volume 33(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Issue 31 (29th July 2022) Authors: Chichili, Gurunadh R.; Smulders, Ronald; Santos, Vicki; Cywin, Beth; Kovanda, Laura; Van Sant, Charles; Malinoski, Frank; Sebastian, Shite; Siber, George; Malley, Richard Journal: Vaccine Issue: Volume 40:Issue 31(2022) Page Start: 4190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗